These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21617542)

  • 1. Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data.
    Yoon EL; Yim HJ; Lee HJ; Lee YS; Kim JH; Jung ES; Kim JH; Seo YS; Yeon JE; Lee HS; Um SH; Byun KS
    J Clin Gastroenterol; 2011; 45(10):893-9. PubMed ID: 21617542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.
    Kim HJ; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI
    Liver Int; 2010 Jul; 30(6):834-40. PubMed ID: 20408946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
    Bae SH; Baek YH; Lee SW; Han SY
    Korean J Gastroenterol; 2010 Dec; 56(6):365-72. PubMed ID: 21173560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy].
    Lee JW; Lee YJ; Lee JJ; Kim JH; Jung YK; Kwon OS; Choi DJ; Kim YS; Kim JH
    Korean J Gastroenterol; 2013 Jan; 61(1):30-6. PubMed ID: 23354347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.
    Kim SB; Song IH; Kim YM; Noh R; Kang HY; Lee HIe; Yang HY; Kim AN; Chae HB; Lee SH; Kim HS; Lee TH; Kang YW; Lee ES; Kim SH; Lee BS; Lee HY
    World J Gastroenterol; 2012 Dec; 18(47):6943-50. PubMed ID: 23322992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy.
    Jang JH; Kim JW; Jeong SH; Myung HJ; Kim HS; Park YS; Lee SH; Hwang JH; Kim N; Lee DH
    J Viral Hepat; 2011 Feb; 18(2):84-90. PubMed ID: 20196804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
    Lee HJ; Eun JR; Lee CH; Hwang JS; Suh JI; Kim BS; Jang BK
    Korean J Hepatol; 2009 Jun; 15(2):179-92. PubMed ID: 19581770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.
    Kim JH; Yim HJ; Jung ES; Jung YK; Kim JH; Seo YS; Yeon JE; Lee HS; Um SH; Byun KS
    J Viral Hepat; 2011 Apr; 18(4):287-93. PubMed ID: 20367793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.
    Yoo BC; Kim JH; Kim TH; Koh KC; Um SH; Kim YS; Lee KS; Han BH; Chon CY; Han JY; Ryu SH; Kim HC; Byun KS; Hwang SG; Kim BI; Cho M; Yoo K; Lee HJ; Hwang JS; Kim YS; Lee YS; Choi SK; Lee YJ; Yang JM; Park JW; Lee MS; Kim DG; Chung YH; Cho SH; Choi JY; Kweon YO; Lee HY; Jeong SH; Yoo HW; Lee HS
    Hepatology; 2007 Oct; 46(4):1041-8. PubMed ID: 17647293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.
    Sohn HR; Min BY; Song JC; Seong MH; Lee SS; Jang ES; Shin CM; Park YS; Hwang JH; Jeong SH; Kim N; Lee DH; Kim JW
    BMC Infect Dis; 2014 Aug; 14():439. PubMed ID: 25125320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients.
    Lee JS; Park ET; Kang SS; Gu ES; Kim JS; Jang DS; Lee KS; Lee JS; Park NH; Bae CH; Baik SK; Yu BJ; Lee SH; Lee EJ; Park SI; Bae M; Shin JW; Choi JH; Gu C; Moon SK; Chun GJ; Kim JH; Kim HS; Choi SK
    Intervirology; 2010; 53(2):83-6. PubMed ID: 19955812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B.
    Yang HW; Lee BS; Lee TH; Lee HY; Nam KW; Kang YW; Chae HB; Kim SH; Kim SB; Lee HIe; Kim AN; Song IH; Lee SH; Kim HS
    Korean J Intern Med; 2010 Dec; 25(4):372-6. PubMed ID: 21179274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study.
    Ko SY; Kwon SY; Choe WH; Kim BK; Kim KH; Lee CH
    Antivir Ther; 2009; 14(4):585-90. PubMed ID: 19578244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
    Yoo BC; Kim JH; Chung YH; Lee KS; Paik SW; Ryu SH; Han BH; Han JY; Byun KS; Cho M; Lee HJ; Kim TH; Cho SH; Park JW; Um SH; Hwang SG; Kim YS; Lee YJ; Chon CY; Kim BI; Lee YS; Yang JM; Kim HC; Hwang JS; Choi SK; Kweon YO; Jeong SH; Lee MS; Choi JY; Kim DG; Kim YS; Lee HY; Yoo K; Yoo HW; Lee HS
    Hepatology; 2007 May; 45(5):1172-8. PubMed ID: 17464992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of 48-week clevudine therapy for chronic hepatitis B].
    Kim MH; Kim KA; Lee JS; Lee HW; Kim HJ; Yun SG; Kim NH; Bae WK; Moon YS
    Korean J Hepatol; 2009 Sep; 15(3):331-7. PubMed ID: 19783882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B.
    Bang SJ; Kim BG; Shin JW; Ju HU; Park BR; Kim MH; Kim CJ; Park JH; Jeong ID; Jung SW; Park NH
    Dig Liver Dis; 2013 Jul; 45(7):600-5. PubMed ID: 23333665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
    Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
    Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.
    Cho JY; Sohn W; Sinn DH; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2017 Jul; 32(4):636-646. PubMed ID: 27809454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.